Measures that target Russia’s core industries will depress consumption and investment
Tim Kobe, the man behind the Apple Store's signature touches, remembers what Jobs taught him about retail design
In offering conflicting opinions within hours, two federal courts have set up a fight at the Supreme Court over the Affordable Care Act
Xiaomi Chief Executive Officer Lei Jun unveils the Mi4, a metal-backed iPhone-esque smartphone with a 5-inch display, the latest Qualcomm Snapdragon chip, and a $320 price tag
A months-long public-relations debacle is taking a heavy toll on the operators of dark pools
The furniture manufacturer of midcentury classics acquires its largest retail outlet
That an accordion-playing parodist has become one of the most enduring musical acts of our time is, well, a little weird
A new report shows young college-educated professionals will wait a long time to see the financial rewards of their degree.
Profiled companies pay the recruiting service, but job-seekers don't
King of Prussia, Pa.
Founders: Dr. Robert Lefkowitz and Dr. Howard Rockman
VC Investment over the last four quarters: $26.1 million
Trevena, founded in January 2008, is a drug discovery company developing pharmaceuticals that target what are known as G-protein coupled receptors. Such drugs make up more than 40% of marketed drugs today, according to Trevena. The company's drug discovery platform is based on research from Duke University Medical Center, including that of founder and National Medal of Science winner Robert Lefkowitz.
Key to startup success: "We've been able to generate the strong investor support for this idea [because] the technology and the opportunity here is very, very unique, and the possibility of unlocking new areas of biology is so significantly different from what's currently out there."